BLUE

bluebird bio Inc

Add to Watchlist

Advanced Chart

0.000

-4.97(-100.000%)1D

Overview
Forecast
Valuation
Earnings

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

9.79M

129.31M

EV/OCF(TTM)

P/S(TTM)

0.46

bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. It markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel), and LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel). ZYNTEGLO is the first gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. SKYSONA is used to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). LYFGENIA is used for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

45.60M

+183.23%

68.30M

+543.61%

69.65M

+80.81%

Estimates Revision

The market is revising Downward the revenue expectations for bluebird bio, Inc. (BLUE) for FY2025, with the revenue forecasts being adjusted by -7.2% over the past three months. During the same period, the stock price has changed by 18.62%.

Revenue Estimates for FY2025

Revise Downward

-7.2%

In Past 3 Month

Stock Price

Go Up

+18.62%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast BLUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLUE is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0

Low

8.00

Averages

8.00

High

8.00

Current: 0

Low

8.00

Averages

8.00

High

8.00

Barclays

Gena Wang

Buy

Maintains

$40 → $8

2025-03-31

Reason

Barclays

Gena Wang

Price Target

$40 → $8

2025-03-31

Maintains

Buy

Reason

Barclays lowered the firm's price target on Bluebird Bio to $8 from $40 and keeps an Overweight rating on the shares. The company reported a Q4 revenue beat with 2024 cell collections largely in line. Guidance for Bluebird's cash runway is Q2 of 2025, with a key focus on closing of merger to avoid potential risks of bankruptcy and liquidation, the analyst tells investors in a research note.

JP Morgan

Eric Joseph

Sell

Hold

Upgrades

n/a

2025-02-24

Reason

JP Morgan

Eric Joseph

Price Target

n/a

2025-02-24

Upgrades

Sell

Hold

Reason

Wells Fargo

Yanan Zhu

Hold

Maintains

$40 → $5

2025-02-24

Reason

Wells Fargo

Yanan Zhu

Price Target

$40 → $5

2025-02-24

Maintains

Hold

Reason

Barclays

Gena Wang

Buy

Maintains

$2 → $40

2024-12-31

Reason

Barclays

Gena Wang

Price Target

$2 → $40

2024-12-31

Maintains

Buy

Reason

Barclays analyst Gena Wang raised the firm's price target on Bluebird Bio to $40 from $2 and keeps an Overweight rating on the shares. The firm updated the company's model to reflect Bluebird's 1:20 reverse split announced in December. The purpose of the reverse split was to meet Nasdaq's listing compliance of minimum bid price, the analyst tells investors in a research note.

Barclays

Gena Wang

Buy

Maintains

$4 → $2

2024-11-15

Reason

Barclays

Gena Wang

Price Target

$4 → $2

2024-11-15

Maintains

Buy

Reason

Barclays analyst Gena Wang lowered the firm's price target on Bluebird Bio to $2 from $4 and keeps an Overweight rating on the shares. The company reported a Q3 revenue miss due to the timing of infusions, the analyst tells investors in a research note.

B of A Securities

Jason Gerberry

Strong Buy

Hold

Downgrades

$3 → $0.5

2024-11-15

Reason

B of A Securities

Jason Gerberry

Price Target

$3 → $0.5

2024-11-15

Downgrades

Strong Buy

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for bluebird bio Inc (BLUE.O) is -0.57, compared to its 5-year average forward P/E of -2.07. For a more detailed relative valuation and DCF analysis to assess bluebird bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.07

Current PE

-0.57

Overvalued PE

-0.78

Undervalued PE

-3.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.78

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.50

Undervalued EV/EBITDA

-3.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

14.11

Current PS

0.19

Overvalued PS

30.47

Undervalued PS

-2.26